Ion channel drug discovery: challenges and future directions

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Sumikawa K, Houghton M, Smith JC, Bell L, Richards BM, Barnard EA. The molecular cloning and characterisation of cDNA coding for the α subunit of the acetylcholine receptor. Nucleic Acids Res.10(19),5809–5822 (1982).
  Medline CASGoogle Scholar
• 2  Herz JM, Thomsen WJ, Yarbrough GG. Molecular approaches to receptors as targets for drug discovery. J. Recept. Signal Transduct. Res.17(5),671–776 (1997).
  Medline CASGoogle Scholar
• 3  Dunlop J, Bowlby M, Peri R et al. Ion channel screening. Comb. Chem. High Throughput Screen11(7),514–522 (2008).
  Medline CASGoogle Scholar
• 4  Tonstad S, Rollema H. Varenicline in smoking cessation. Expert Rev. Respir. Med.4(3),291–299 (2010).
  Medline CASGoogle Scholar
• 5  Weisenberg JL, Wong M. Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures. Neuropsychiatr. Dis. Treat.7(1),409–414 (2011).
  Medline CASGoogle Scholar
• 6  Doggrell SA. Intrathecal ziconotide for refractory pain. Expert Opin. Invest. Drugs13(7),875–877 (2004).
  Medline CASGoogle Scholar
• 7  Opar A. Excitement mounts for first disease-modifying cystic fibrosis drugs. Nat. Rev. Drug Discov.10(7),479–480 (2011).
  Medline CASGoogle Scholar
• 8  Krauss GL, Bar M, Biton V et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol. Scand.125(1),8–15 (2011).
  MedlineGoogle Scholar
• 9  Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov.9(3),203–214 (2010).
  Medline CASGoogle Scholar
• 10  Borgeat A, Aguirre J. Update on local anesthetics. Curr. Opin. Anaesthesiol.23(4),466–471 (2010).
  MedlineGoogle Scholar
• 11  Pitt B. Diversity of calcium antagonists. Clin. Ther.19(Suppl. A),3–17 (1997).
  Medline CASGoogle Scholar
• 12  Garty H, Rudy B, Karlish SJ. A simple and sensitive procedure for measuring isotope fluxes through ion-specific channels in heterogenous populations of membrane vesicles. J. Biol. Chem.258(21),13094–13099 (1983).
  Medline CASGoogle Scholar
• 13  Maddox RW, Arnold WS, Dewell WM Jr. Extreme hyperkalemia associated with amiloride. South Med. J.78(3),365 (1985).
  Medline CASGoogle Scholar
• 14  Christensen BM, Perrier R, Wang Q et al. Sodium and potassium balance depends on αENaC expression in connecting tubule. J. Am. Soc. Nephrol.21(11),1942–1951 (2010).
  Medline CASGoogle Scholar
• 15  Jurkat-Rott K, Lerche H, Weber Y, Lehmann-Horn F. Hereditary channelopathies in neurology. Adv. Exp. Med. Biol.686,305–334 (2010).
  MedlineGoogle Scholar
• 16  Roberts JD, Gollob MH. The genetic and clinical features of cardiac channelopathies. Future Cardiol.6(4),491–506 (2010).
  MedlineGoogle Scholar
• 17  Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. From genes to pain: Na(v)1.7 and human pain disorders. Trends Neurosci.30(11),555–563 (2007).
  Medline CASGoogle Scholar
• 18  Cox JJ, Reimann F, Nicholas AK et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature444(7121),894–898 (2006).
  Medline CASGoogle Scholar
• 19  Chadha V, Alon US. Hereditary renal tubular disorders. Semin. Nephrol.29(4),399–411 (2009).
  Medline CASGoogle Scholar
• 20  Tobin MD, Tomaszewski M, Braund PS et al. Common variants in genes underlying monogenic hypertension and hypotension and blood pressure in the general population. Hypertension51(6),1658–1664 (2008).
  Medline CASGoogle Scholar
• 21  Ji W, Foo JN, O’Roak BJ et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat. Genet.40(5),592–599 (2008).
  Medline CASGoogle Scholar
• 22  Cao YQ. Voltage-gated calcium channels and pain. Pain126(1–3),5–9 (2006).
  Medline CASGoogle Scholar
• 23  Kim D, Song I, Keum S et al. Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking α (1G) T-type Ca(2+) channels. Neuron31(1),35–45 (2001).
  Medline CASGoogle Scholar
• 24  Kaczmarek LK. Non-conducting functions of voltage-gated ion channels. Nat. Rev. Neurosci.7(10),761–771 (2006).▪ Comprehensive review of the literature on nonconducting functions of ion channels.
  Medline CASGoogle Scholar
• 25  Moosmang S, Haider N, Bruderl B, Welling A, Hofmann F. Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2. Circ. Res.98(1),105–110 (2006).
  Medline CASGoogle Scholar
• 26  Cha TJ, Ehrlich JR, Chartier D, Qi XY, Xiao L, Nattel S. Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation113(14),1730–1737 (2006).▪ Use of a potent, selective peptide blocker of Kir3 channels to demonstrate the role of this channel in atrial repolarization in vivo.
  Medline CASGoogle Scholar
• 27  Herrington J, Zhou YP, Bugianesi RM et al. Blockers of the delayed-rectifier potassium current in pancreatic β-cells enhance glucose-dependent insulin secretion. Diabetes55(4),1034–1042 (2006).
  Medline CASGoogle Scholar
• 28  Lu Q, An WF. Impact of novel screening technologies on ion channel drug discovery. Comb. Chem. High Throughput Screen11(3),185–194 (2008).
  Medline CASGoogle Scholar
• 29  Terstappen GC, Roncarati R, Dunlop J, Peri R. Screening technologies for ion channel drug discovery. Future Med. Chem.2(5),715–730 (2010).▪▪ Thorough review of ion channel screening technologies.
  CASGoogle Scholar
• 30  Stankovich L, Wicks D, Despotovski S, Liang D. Atomic absorption spectroscopy in ion channel screening. Assay Drug Dev. Technol.2(5),569–574 (2004).
  Medline CASGoogle Scholar
• 31  Ransom RW, Stec NL. Inhibition of N-methyl-D-aspartate evoked sodium flux by MK-801. Brain Res.444(1),25–32 (1988).
  Medline CASGoogle Scholar
• 32  Arranz E, Diaz JA, Vega S et al. Synthesis and pharmacological evaluation of 2, 3-dihydro-3-oxo-4H-thieno[3,4-e] [1,2,4] thiadiazine 1,1-dioxides as voltage-dependent calcium channel blockers. Eur. J. Med. Chem.35(7–8),751–759 (2000).
  Medline CASGoogle Scholar
• 33  Cheng CS, Alderman D, Kwash J et al. A high-throughput hERG assay with a new look. Drug Dev. Ind. Pharm.28(2),177–191 (2002).
  Medline CASGoogle Scholar
• 34  Abbadie C, McManus OB, Sun SY et al. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J. Pharmacol. Exp. Ther.334(2),545–555 (2010).
  Medline CASGoogle Scholar
• 35  Hansen KB, Mullasseril P, Dawit S et al. Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. J. Pharmacol. Exp. Ther.333(3),650–662 (2010).
  Medline CASGoogle Scholar
• 36  Lewis LM, Bhave G, Chauder BA et al. High-throughput screening reveals a small-molecule inhibitor of the renal outer medullary potassium channel and Kir7.1. Mol. Pharmacol.76(5),1094–1103 (2009).
  Medline CASGoogle Scholar
• 37  Felix JP, Williams BS, Priest BT et al. Functional assay of voltage-gated sodium channels using membrane potential-sensitive dyes. Assay Drug Dev. Technol.2(3),260–268 (2004).
  Medline CASGoogle Scholar
• 38  Priest BT, Swensen AM, McManus OB. Automated electrophysiology in drug discovery. Curr. Pharm. Des.13(23),2325–2337 (2007).
  Medline CASGoogle Scholar
• 39  Xia M, Imredy JP, Koblan KS, Bennett P, Connolly TM. State-dependent inhibition of L-type calcium channels: cell-based assay in high-throughput format. Anal. Biochem.327(1),74–81 (2004).
  Medline CASGoogle Scholar
• 40  Baxter DF, Kirk M, Garcia AF et al. A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J. Biomol. Screen7(1),79–85 (2002).
  Medline CASGoogle Scholar
• 41  Zou B, Yu H, Babcock JJ et al. Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-á-go-go related gene potassium channels. Assay Drug Dev. Technol.8(6),743–754 (2010).
  Medline CASGoogle Scholar
• 42  Clare JJ. Targeting ion channels for drug discovery. Discov. Med.9(46),253–260 (2010).
  MedlineGoogle Scholar
• 43  Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol. Rev.38(4),321–416 (1986).
  Medline CASGoogle Scholar
• 44  Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol.73(1),157–169 (2008).
  Medline CASGoogle Scholar
• 45  Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol.58(3),591–600 (2000).
  Medline CASGoogle Scholar
• 46  Li SX, Huang S, Bren N et al. Ligand-binding domain of an α7-nicotinic receptor chimera and its complex with agonist. Nat. Neurosci.14(10),1253–1259 (2011).
  Medline CASGoogle Scholar
• 47  Large CH, Kalinichev M, Lucas A et al. The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res.85(1),96–106 (2009).
  Medline CASGoogle Scholar
• 48  Jarvis MF, Honore P, Shieh CC et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl Acad. Sci. USA104(20),8520–8525 (2007).
  Medline CASGoogle Scholar
• 49  Sugioka N, Koyama H, Kawakubo M et al. Age-dependent alteration of the serum-unbound fraction of nicardipine, a calcium-channel blocker, in man. J. Pharm. Pharmacol.48(12),1327–1331 (1996).
  Medline CASGoogle Scholar
• 50  Plum A, Muller LK, Jansen JA. The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma. Methods Find. Exp. Clin. Pharmacol.22(3),139–143 (2000).
  Medline CASGoogle Scholar
• 51  Gever JR, Soto R, Henningsen RA et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br. J. Pharmacol.160(6),1387–1398 (2010).
  Medline CASGoogle Scholar
• 52  Ratliff KS, Petrov A, Eiermann GJ et al. An automated electrophysiology serum shift assay for K(V) channels. Assay Drug Dev. Technol.6(2),243–253 (2008).
  Medline CASGoogle Scholar
• 53  Ragsdale DS, Scheuer T, Catterall WA. Frequency and voltage-dependent inhibition of Type 2A Na⁺ channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol. Pharmacol.40(5),756–765 (1991).
  Medline CASGoogle Scholar
• 54  Catterall WA. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv. Neurol.79,441–456 (1999).
  Medline CASGoogle Scholar
• 55  Hildebrand ME, Smith PL, Bladen C et al. A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain. Pain152(4),833–843 (2011).
  Medline CASGoogle Scholar
• 56  Capelli AM, Castelletti L, Salvagno C et al. Identification of novel α7 nAChR positive allosteric modulators with the use of pharmacophore in silico screening methods. Bioorg. Med. Chem. Lett.20(15),4561–4565 (2010).▪ Great example of using the output of high-throughput screening to build a pharmacophore model and screen in silico for novel scaffolds.
  Medline CASGoogle Scholar
• 57  Dinklo T, Shaban H, Thuring JW et al. Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazoleme thanol (JNJ-1930942), a novel positive allosteric modulator of the {α}7 nicotinic acetylcholine receptor. J. Pharmacol. Exp. Ther.336(2),560–574 (2011).
  Medline CASGoogle Scholar
• 58  Lee CH, Zhu C, Malysz J et al. α4β2 neuronal nicotinic receptor positive allosteric modulation: An approach for improving the therapeutic index of α4β2 nAChR agonists in pain. Biochem. Pharmacol.82(8),959–966 (2011).
  Medline CASGoogle Scholar
• 59  Zhu CZ, Chin CL, Rustay NR et al. Potentiation of analgesic efficacy but not side effects: Co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats. Biochem. Pharmacol.82(8),967–976 (2011).▪ Increased therapeutic potential of modulators of α4β2 nicotinic acetylcholine receptors by co-administration of an agonist with a positive allosteric modulator.
  Medline CASGoogle Scholar
• 60  Swanson DM, Dubin AE, Shah C et al. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem.48(6),1857–1872 (2005).
  Medline CASGoogle Scholar
• 61  Lipscombe D, Raingo J. Alternative splicing matters: N-type calcium channels in nociceptors. Channels (Austin)1(4),225–227 (2007).
  MedlineGoogle Scholar
• 62  Ermolinsky BS, Skinner F, Garcia I et al. Upregulation of STREX splice variant of the large conductance Ca²⁺-activated potassium (BK) channel in a rat model of mesial temporal lobe epilepsy. Neurosci. Res.69(1),73–80 (2010).
  MedlineGoogle Scholar
• 63  Nimigean CM. A radioactive uptake assay to measure ion transport across ion channel-containing liposomes. Nat. Protoc.1(3),1207–1212 (2006).
  Medline CASGoogle Scholar
• 64  Schieder M, Rotzer K, Bruggemann A, Biel M, Wahl-Schott C. Planar patch clamp approach to characterize ionic currents from intact lysosomes. Sci. Signal3(151),pl3 (2010).▪ Describes an assay for ion channels present in membranes of intracellular organelles.
  Medline CASGoogle Scholar
• 65  Nishimune H. Transsynaptic channelosomes: non-conducting roles of ion channels in synapse formation. Channels (Austin)5(5),432–439 (2011).
  Medline CASGoogle Scholar
• 66  Feinshreiber L, Singer-Lahat D, Friedrich R et al. Non-conducting function of the Kv2.1 channel enables it to recruit vesicles for release in neuroendocrine and nerve cells. J. Cell. Sci.123(Part 11),1940–1947 (2010).
  Medline CASGoogle Scholar
• 67  Maffie J, Rudy B. Weighing the evidence for a ternary protein complex mediating A-type K⁺ currents in neurons. J. Physiol.586(Pt 23),5609–5623 (2008).
  Medline CASGoogle Scholar
• 68  Meadows LS, Isom LL. Sodium channels as macromolecular complexes: implications for inherited arrhythmia syndromes. Cardiovasc. Res.67(3),448–458 (2005).
  Medline CASGoogle Scholar
• 69  Wang Y, Brittain JM, Jarecki BW et al.In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation. J. Biol. Chem.285(33),25296–25307 (2010).
  Medline CASGoogle Scholar
• 70  Ameen C, Strehl R, Bjorquist P, Lindahl A, Hyllner J, Sartipy P. Human embryonic stem cells: current technologies and emerging industrial applications. Crit. Rev. Oncol. Hematol.65(1),54–80 (2008).
  MedlineGoogle Scholar
• 71  Sartipy P, Bjorquist P, Strehl R, Hyllner J. The application of human embryonic stem cell technologies to drug discovery. Drug Discov. Today12(17–18),688–699 (2007).
  Medline CASGoogle Scholar
• 72  Liu Q, Huang H, Cai H et al. Embryonic stem cells as a novel cell source of cell-based biosensors. Biosens. Bioelectron22(6),810–815 (2007).
  Medline CASGoogle Scholar
• 73  Stastna M, Abraham MR, Van Eyk JE. Cardiac stem/progenitor cells, secreted proteins, and proteomics. FEBS Lett.583(11),1800–1807 (2009).
  Medline CASGoogle Scholar
• 74  Dick E, Rajamohan D, Ronksley J, Denning C. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem. Soc. Trans38(4),1037–1045 (2010).
  Medline CASGoogle Scholar
• 75  McNeish J, Roach M, Hambor J et al. High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors. J. Biol. Chem.285(22),17209–17217 (2010).▪ Use of stem cell-derived neurons for HTS screening for AMPA modulators.
  Medline CASGoogle Scholar
• 76  He JQMJ, Anson B. Use of pluripotent stem cell-derived cardiomyocytes to understand mechanisms of cardiotoxic compounds. Cell Notes23,10–12 (2009).
  Google Scholar
• 77  Cezar GG. Can human embryonic stem cells contribute to the discovery of safer and more effective drugs? Curr. Opin. Chem. Biol.11(4),405–409 (2007).
  Medline CASGoogle Scholar
• 78  Asai Y, Tada M, Otsuji TG, Nakatsuji N. Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode array system: an ideal hybrid model assay for drug development. Curr. Stem Cell Res. Ther.5(3),227–232 (2010).
  Medline CASGoogle Scholar
• 79  Jensen J, Hyllner J, Bjorquist P. Human embryonic stem cell technologies and drug discovery. J. Cell. Physiol.219(3),513–519 (2009).
  Medline CASGoogle Scholar
• 80  Habib M, Caspi O, Gepstein L. Human embryonic stem cells for cardiomyogenesis. J. Mol. Cell. Cardiol.45(4),462–474 (2008).
  Medline CASGoogle Scholar
• 81  Yazawa M, Hsueh B, Jia X et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature471(7337),230–234 (2011).
  Medline CASGoogle Scholar
• 82  Wu J, Shih HP, Vigont V et al. Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington’s disease treatment. Chem. Biol.18(6),777–793 (2011).
  Medline CASGoogle Scholar
• 83  Sanz LM, Jimenez-Diaz MB, Crespo B et al. Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen. Antimicrob. Agents Chemother.55(12),5740–5745 (2011).
  Medline CASGoogle Scholar
• 84  McLaughlin J, Markovtsov V, Li H et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J. Cancer Res. Clin. Oncol.136(1),99–113 (2010).
  Medline CASGoogle Scholar
• 85  Saxe JP, Wu H, Kelly TK et al. A phenotypic small-molecule screen identifies an orphan ligand-receptor pair that regulates neural stem cell differentiation. Chem. Biol.14(9),1019–1030 (2007).
  Medline CASGoogle Scholar
• 86  Roos J, DiGregorio PJ, Yeromin AV et al. STIM1, an essential and conserved component of store-operated Ca²⁺ channel function. J. Cell Biol.169(3),435–445 (2005).
  Medline CASGoogle Scholar
• 87  Zhang SL, Yeromin AV, Zhang XH et al. Genome-wide RNAi screen of Ca(2+) influx identifies genes that regulate Ca(2+) release-activated Ca(2+) channel activity. Proc. Natl Acad. Sci. USA103(24),9357–9362 (2006).
  Medline CASGoogle Scholar
• 88  Coste B, Mathur J, Schmidt M et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science330(6000),55–60 (2010).▪▪ Identification of two novel mechano-sensitive channels by expression profiling and RNA interference knockdown.
  Medline CASGoogle Scholar
• 89  Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr. Opin. Pharmacol.9(5),580–588 (2009).
  Medline CASGoogle Scholar
• 90  Teichert RW, Olivera BM. Natural products and ion channel pharmacology. Future Med. Chem.2(5),731–744 (2010).
  Google Scholar
• 91  Molinari G. Natural products in drug discovery: present status and perspectives. Adv. Exp. Med. Biol.65(5),13–27 (2009).
  Google Scholar
• 92  Harvey AL. Natural products in drug discovery. Drug Discov. Today13(19–20),894–901 (2008).
  Medline CASGoogle Scholar
• 93  Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat. Rev. Drug Discov.8(1),69–85 (2009).▪ Comprehensive review of the status and potential of drug discovery based on marine natural products.
  Medline CASGoogle Scholar
• 94  Escoubas P, King GF. Venomics as a drug discovery platform. Expert Rev. Proteomics6(3),221–224 (2009).
  Medline CASGoogle Scholar
• 95  Chi V, Pennington MW, Norton RS et al. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon59(4),529–546 (2011).
  MedlineGoogle Scholar
• 96  Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res.58(21),4871–4879 (1998).
  Medline CASGoogle Scholar
• 97  Buti M, Esteban R. 1990–2010: two decades of interferon-based therapy. Clin. Liver Dis.15(3),473–482 (2011).
  MedlineGoogle Scholar
• 98  Mochly-Rosen D, Fuchs S. Monoclonal anti-acetylcholine-receptor antibodies directed against the cholinergic binding site. Biochemistry20(20),5920–5924 (1981).
  Medline CASGoogle Scholar
• 99  Watters D, Maelicke A. Organization of ligand binding sites at the acetylcholine receptor: a study with monoclonal antibodies. Biochemistry22(8),1811–1819 (1983).
  Medline CASGoogle Scholar
• 100  Buell G, Chessell IP, Michel AD et al. Blockade of human P2X7 receptor function with a monoclonal antibody. Blood92(10),3521–3528 (1998).
  Medline CASGoogle Scholar
• 101  Zhou BY, Ma W, Huang XY. Specific antibodies to the external vestibule of voltage-gated potassium channels block current. J. Gen. Physiol.111(4),555–563 (1998).▪▪ Pioneering report of antibodies that block ion channel conduction. The same approach has been successfully used by other researchers and for other ion channel types.
  Medline CASGoogle Scholar
• 102  Xu SZ, Zeng F, Lei M et al. Generation of functional ion-channel tools by E3 targeting. Nat. Biotechnol.23(10),1289–1293 (2005).
  Medline CASGoogle Scholar
• 103  Naylor J, Milligan CJ, Zeng F, Jones C, Beech DJ. Production of a specific extracellular inhibitor of TRPM3 channels. Br. J. Pharmacol.155(4),567–573 (2008).
  Medline CASGoogle Scholar
• 104  Klionsky L, Tamir R, Holzinger B et al. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid Type 1 blocks channel activation. J. Pharmacol. Exp. Ther.319(1),192–198 (2006).
  Medline CASGoogle Scholar
• 105  Gomez-Varela D, Zwick-Wallasch E, Knotgen H et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res.67(15),7343–7349 (2007).
  Medline CASGoogle Scholar
• 106  Thiel KA. Structure-aided drug design’s next generation. Nat. Biotechnol.22(5),513–519 (2004).
  Medline CASGoogle Scholar
• 107  Doyle DA, Morais Cabral J, Pfuetzner RA et al. The structure of the potassium channel: molecular basis of K⁺ conduction and selectivity. Science280(5360),69–77 (1998).
  Medline CASGoogle Scholar
• 108  Jamieson C, Maclean JK, Brown CI et al. Structure based evolution of a novel series of positive modulators of the AMPA receptor. Bioorg. Med. Chem. Lett.21(2),805–811 (2011).
  Medline CASGoogle Scholar
• 109  de Groot MJ. Understanding ion channels using computational approaches. Future Med. Chem.2(5),697–701 (2010).
  CASGoogle Scholar
• 110  Vinik AI, Tuchman M, Safirstein B et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain128(1–2),169–179 (2007).
  Medline CASGoogle Scholar
• 111  Rao RD, Flynn PJ, Sloan JA et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a Phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer112(12),2802–2808 (2008).
  Medline CASGoogle Scholar
• 112  Ataga KI, Reid M, Ballas SK et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a Phase 3 randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br. J. Haematol.153(1),92–104 (2011).
  Medline CASGoogle Scholar
• 113  Chizh BA, O’Donnell MB, Napolitano A et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain132(1–2),132–141 (2007).
  Medline CASGoogle Scholar
• 114  Keystone EC, Wang MM, Layton M, Hollis S, McInnes IB. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Annu. Rheum. Dis. doi:10.1136/ard.2010.143578 (2011) (Epub ahead of print).
  Google Scholar
• 115  Ataga KI, Smith WR, De Castro LM et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood111(8),3991–3997 (2008).
  Medline CASGoogle Scholar
• 116  Stehouwer JS, Goodman MM. Fluorine-18 radiolabeled PET tracers for imaging monoamine transporters: dopamine, serotonin, and norepinephrine. PET Clin.4(1),101–128 (2009).
  MedlineGoogle Scholar
• 117  Mony L, Kew JN, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br. J. Pharmacol.157(8),1301–1317 (2009).
  Medline CASGoogle Scholar
• 118  Bursi R, Erdemli G, Campbell R et al. Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576. Psychopharmacology (Berl.)218(4),713–724 (2011).
  Medline CASGoogle Scholar
• 119  Melese T, Lin SM, Chang JL, Cohen NH. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat. Med.15(5),502–507 (2009).▪ Compelling call for industry–academic collaborations and precompetitive consortia in drug discovery.
  Medline CASGoogle Scholar
• 120  Ward SE, Bax BD, Harries M. Challenges for and current status of research into positive modulators of AMPA receptors. Br. J. Pharmacol.160(2),181–190 (2010).
  Medline CASGoogle Scholar
• 121  Norman P. Ion Channel Modulator Pipelines: Targets and Agents in Development. Cambridge Healthtech Institute, Needham, MA, USA (2009).
  Google Scholar
• 122  Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs25(2),89–107 (2011).
  Medline CASGoogle Scholar
• 201  Amgen Inc.: WO108154 (2010).
  Google Scholar
• 301  The New York Times. Suicide warnings for two anti-smoking drugs, www.nytimes.com/2009/07/02/health/02drug.html
  Google Scholar
• 302  Molecular Devices. IonWorks Barracuda Automated Patch Clamp System, www.moleculardevices.com/Products/Instruments/Automated-Electrophysiology/IonWorks-Barracuda.html
  Google Scholar
• 303  ClinicalTrials.gov http://clinicaltrials.gov
  Google Scholar
• 304  PubMed.gov www.ncbi.nlm.nih.gov/pubmed
  Google Scholar
• 305  Alzheimer Research Forum www.alzforum.org/dis/tre/drc/detail.asp?id=125
  Google Scholar
• 306  IFPMA Clinical Trials Portal. http://clinicaltrials.ifpma.org/clinicaltrials/no_cache/en/myportal/index.htm
  Google Scholar
• 307  National Institute of Mental Health. Clinical Trials. www.nimh.nih.gov/trials/index.shtml
  Google Scholar